US5846564A - Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection - Google Patents
Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection Download PDFInfo
- Publication number
- US5846564A US5846564A US08/875,632 US87563297A US5846564A US 5846564 A US5846564 A US 5846564A US 87563297 A US87563297 A US 87563297A US 5846564 A US5846564 A US 5846564A
- Authority
- US
- United States
- Prior art keywords
- ipvp
- composition according
- composition
- effervescent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/12—Iodine, e.g. iodophors; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- This invention relates to an iodinated polyvinylpyrrolidone-based effervescent composition.
- Iodine has long been used in various pharmaceutical forms (solution, tincture) in the fine disinfection of small wounds. Despite its efficacy, application of the product is limited due to the fact that it presents a certain number of side effects.
- IPVP Iodinated polyvinylpyrrolidone
- PVP polyvinylpyrrolidone
- iodine Owing to its complexation with the polyvinylpyrrolidone molecule, the iodine contained in the complex is released slowly and gradually.
- IPVP is characterized by a wide range of applications, principally in the prophylactic field:
- This compound is a broad-spectrum antiseptic:
- bactericidal on all bacteria including chlamydiae and mycoplasms,
- IPVP Iodinated polyvinylpyrrolidone
- IPVP tablets have already been described but with specific reference to mucoadhesive and local use.
- the IPVP tablets present in fact the major drawback of dissolving very slowly in aqueous media.
- compositions notably containing an iodine carrier which may be polyvinylpyrrolidone, an iodide or an iodine compound, an oxidizing agent, an acid or a base in powder form.
- an iodine carrier which may be polyvinylpyrrolidone, an iodide or an iodine compound, an oxidizing agent, an acid or a base in powder form.
- the latter two compounds form an effervescent couple.
- This composition does not, however, comprise iodinated polyvinylpyrrolidone, a complex which has to be formed before it can be integrated in a composition.
- the composition does not contain a disintegrating agent and consequently cannot be used for the extemporaneous production of IPVP solutions, but only for forming foam, as indicated in the abstracts hereabove mentioned.
- Patent GB-A-2 108 386 (AUCHINCLOSS) describes compositions in dry forms containing an iodine source, such as a complex of polyvinylpyrrolidone and iodine, a non-reducing acid and a tensioactive agent capable of combining with iodine to form an iodophor.
- an iodine source such as a complex of polyvinylpyrrolidone and iodine, a non-reducing acid and a tensioactive agent capable of combining with iodine to form an iodophor.
- Patent application PCT/GB 90 01 423 discloses a composition comprising an inorganic halide soluble in water, a strong oxidizing agent which will react with the halide so as to generate hypohalic ions, sulfamic acid, and a carbonate or bicarbonate soluble in water in order to produce, in reaction with the acid, an effervescent effect.
- a disintegrating agent is not mentioned in this application which preferentially concerns chlorine-based tablets.
- U.S. Pat. No. 3,136,692 (STRONG CORB ARNER, INC.) concerns effervescent compositions containing polyvinylpyrrolidone, a solid organic acid and a therapeutic agent or a flavoring agent. Neither iodinated polyvinylpyrrolidone nor a disintegrating agent is mentioned in this patent.
- compositions which contain IPVP and which also permit extemporaneous, reproducible and easily applicable preparation of IPVP solutions.
- IPVP IPVP
- effervescent agents and disintegrating agents in the form of granules or tablets, is preserved over a long period of time and rapidly gives an IPVP solution through the contact of this association with an aqueous medium.
- This invention therefore relates to an effervescent composition for the extemporaneous preparation of IPVP solutions comprising in synergetic quantities:
- IPVP iodinated polyvinylpyrrolidone
- At least one disintegrating agent at least one disintegrating agent.
- compositions concerned by this invention possess the advantage of dissolving in at least ten minutes, and generally in three to five minutes, thus permitting an extemporaneous preparation of IPVP solution in contrast to the compositions described in the prior art which contain no disintegrating agent. These compositions also make it possible to obtain reproducible iodine levels in solution.
- Such a composition advantageously comprises, by weight, 0.1% to 99%, preferentially 10% to 90% and even more preferentially 20% to 60% of IPVP in relation to the total weight of the composition.
- Said effervescent agent is advantageously an association comprising citric acid and carbonic acid, or their derivatives. However, it may be any association of organic acid/carbonate substances giving effervescence.
- the citric acid derivatives which may be used in such a couple are, in particular, monosodium citrate or monohydrated or anhydrous citric acid.
- a derivative of carbonic acid may be monosodium carbonate.
- Citric acid and carbonic acid, or their derivatives, are advantageously contained in approximately identical quantities.
- the disintegrating agent may be a substance presenting a structural similarity to IPVP; it possesses in particular a reticulated polyvinylpyrrolidone (PVP), or a reticulated carboxymethylcellulose.
- PVP reticulated polyvinylpyrrolidone
- reticulated carboxymethylcellulose a substance presenting a disintegrating effect such as defined above.
- composition according to this invention comprises, by weight, 40% to 60% of effervescent agent and 2% to 10%, preferentially 4% to 6%, of disintegrating agent.
- the composition is presented in the form of a powder, granules or tablets.
- the invention may also contain a buffer system with a pH close to 6, so as to limit the degradation of the IPVP.
- a buffer system with a pH close to 6, so as to limit the degradation of the IPVP.
- Such a buffer effect is advantageously provided through salts, such as KH 2 PO 4 or by sodium hydroxide.
- a water-repellent substance may also be contained in the composition in order to prevent moisture decomposition.
- a water-repellent substance may be, for example, colloidal silica.
- composition according to the invention may also contain one or more surfactants.
- composition is in the form of granules consisting of:
- an external phase comprising a disintegrating agent and a lubricant.
- This invention also relates to the use of a composition such as described above for the disinfection of skin and mucous membranes.
- compositions have unquestionable practical as well as economic advantages as they facilitate the transportation and handling of IPVP.
- the tablets according to the invention may be obtained by a process in which the IPVP and the effervescent agent are mixed, and then the disintegrating agent and the other constituents of the tablets are introduced.
- the tablet is then shaped using a compressing machine.
- Granules according to the invention may be obtained by a process similar to that used for tablets, the tablet compression stage being replaced by a compacting stage and then a granulation stage, for example using an ERWEKA AR 400 machine.
- Granules with internal and external phases according to the invention may be obtained by a wet granulation process in which:
- the internal phase is constituted by IPVP with, if required, a surfactant and an effervescent couple,
- the external phase comprising the other constituents of the composition is added.
- step (3) Add the previously sifted colloidal silica and the disintegrating agent to the mixture obtained in step (2).
- Humidity 3 g of water per m 3 of dry air, i.e. 20% RH at 20° C.
- anhydrous citric acid is replaced, at equivalent weight, by monohydrated citric acid.
- step (3) pour the grain obtained in step (3) in a thin layer on a heating plate.
- step (5) Granulate the grain obtained in step (5) using an ERWEKA AR 400 granulating machine or equivalent on a grill 800 ⁇ m in diameter.
- step (8) Calibrate the grain obtained in step (7) on a 800 ⁇ m sieve.
- step (9) Pour the mixture obtained in step (8) into a TURBULA type mixer or equivalent.
- nonoxymol may be replaced by Cremophor, Tween 80 or any other equivalent surfactant.
- lactose may be added to the compounds of this layer.
- compositions Two types of compositions, one containing a disintegrating agent, reticulated PVP (polyplasdone XL), and the other without this agent, respectively called GAL 01.16 and GAL 01.17, were produced by direct compression as described in Example 1.
- Table II shows that the GAL 01.16 tablets dissolve in approximately 4 minutes, whereas the tablets without disintegrating agent GAL 01.17 have still not dissolved after 24 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
______________________________________ GAL FORMULA 01-10 Amount % (in weight) ______________________________________ IPVP (iodinated PVP) 30/06 46.70 Anhydrous citric acid agent 20.45 Monosodium carbonate effervescent 24.55 Reticulated PVP (Polyplasdone XL) 5 Polyethylene glycol 6000 (PEG) 3 (micronized) Colloidal silica (Aerosil R 972) 0.3 Theoretical weight 2.14 g ______________________________________
TABLE 1 __________________________________________________________________________ Composition of granules obtained according to Example 2 FORMULATIONS Weight % GAL 02.11 GAL 02.13 GAL 02.14 GAL 02.15 GAL 02.16 __________________________________________________________________________ Inner layer IPVP 30/06 46.7 41.3 21.6 35.05 30.28 Surfactant 0.94 0.49 0.7 0.6 (20% Nonoxynol solution) KH.sub.2 PO.sub.4 0.2 N 0.8 0.69 solution) NaOH (0.2 N 0.147 0.127 solution) Monosodium 24.53 carbonate Anhydrous 20.45 citric acid Micronized PEG 3 6000 Outer layer Micronized PEG 2.97 2.99 3 3 6000 Monosodium 27.75 39.02 30.81 33.61 citrate Monosodium 21.78 30.63 24.19 26.39 carbonate Reticulated PVP 5.02 4.96 4.97 5 5 (Polyplasdone XL) Colloidal 0.3 0.3 0.29 0.3 0.3 silica (Aerosil R972) Amount of IPVP 1 g 1 g 500 mg 750 mg 650 mg per tablet Theoretical 2.14 g 2.4 g 2.3 g 2.14 g 2.14 g weight (20 mm tablet) __________________________________________________________________________
TABLE II ______________________________________ GAL 01.16 GAL 01.17 ______________________________________ IPVP 30/06 36.7 38.6 Monosodium citrate 30.81 33.5 Monosodium carbonate 24.19 26.31 Polyplasdone XL 5 -- Aerosil R 972 0.3 0.33 Sodium benzoate 3 3.26 IPVP amount of per tablet 750 mg 750 mg Theoretical weight of tablets (20 mm) 2.044 g 2.049 g Disintegration time (10 ml) 4 min >24 hours ______________________________________
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9501047A FR2729858B1 (en) | 1995-01-30 | 1995-01-30 | EFFERVESCENT COMPOSITION BASED ON IODIZED POLYVINYLPYRROLIDONE AND USE FOR DISINFECTION |
FR9501047 | 1995-01-30 | ||
PCT/FR1996/000157 WO1996023510A1 (en) | 1995-01-30 | 1996-01-30 | Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection |
Publications (1)
Publication Number | Publication Date |
---|---|
US5846564A true US5846564A (en) | 1998-12-08 |
Family
ID=9475639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/875,632 Expired - Fee Related US5846564A (en) | 1995-01-30 | 1996-01-30 | Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection |
Country Status (7)
Country | Link |
---|---|
US (1) | US5846564A (en) |
EP (1) | EP0804208A1 (en) |
JP (1) | JPH10513170A (en) |
AU (1) | AU4667396A (en) |
CA (1) | CA2211586A1 (en) |
FR (1) | FR2729858B1 (en) |
WO (1) | WO1996023510A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440926B1 (en) * | 1997-04-14 | 2002-08-27 | The Procter & Gamble Company | Effervescent compositions and dry effervescent granules |
US20060177511A1 (en) * | 2002-01-16 | 2006-08-10 | 3M Innovative Properties Company | Antiseptic compositions and methods |
US20060246027A1 (en) * | 2005-05-02 | 2006-11-02 | Tanner Paul R | Personal care composition |
WO2011089584A1 (en) * | 2010-01-25 | 2011-07-28 | Modi-Mundipharma Pvt. Ltd | Process for the preparation of a granular oral composition |
IT202100003764A1 (en) * | 2021-02-18 | 2022-08-18 | Diego Zito | BIOCIDAL DETERGENT |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091629A1 (en) | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
PT1708686E (en) | 2003-12-31 | 2011-04-20 | Cima Labs Inc | Generally linear effervescent oral fentanyl dosage form and methods of administering |
EP1708685B1 (en) | 2003-12-31 | 2011-03-09 | Cima Labs Inc. | Effervescent oral opiate dosage forms and methods of administering oxycodone |
WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
FR2900795B1 (en) * | 2006-05-15 | 2011-04-29 | Solutio Lab | DETERGENT FORMULATION AND DISINFECTANT IN DIVIDED SOLID FORM CONTAINING AS ACTIVE INGREDIENT A PVP IODEE / POTASSIUM IODIDE ASSOCIATION |
WO2016015691A1 (en) | 2014-07-30 | 2016-02-04 | Albert SARKESSYAN | A pharmaceutical composition having antibacterial and virucidal effects |
JP6955784B2 (en) * | 2017-07-04 | 2021-10-27 | フルケム リミテッドFluchem Ltd | An antiviral and antibacterial composition for eyes, oral cavity, nasal cavity or inhalation containing a solid composition containing an iodo agent and sodium chloride having improved water solubility and an aqueous solution thereof. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089606A (en) * | 1989-01-24 | 1992-02-18 | Minnesota Mining And Manufacturing Company | Water-insoluble polysaccharide hydrogel foam for medical applications |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3136692A (en) * | 1961-06-30 | 1964-06-09 | Strong Cobb Arner Inc | Effervescent composition containing polyvinylpyrrolidone |
GB2108386B (en) * | 1981-10-26 | 1985-11-27 | Auchincloss Thomas R | Iodine-containing disinfectant compositions |
JPS63225308A (en) * | 1986-04-03 | 1988-09-20 | Sanyo Chem Ind Ltd | Solid iodophor composition |
GB8920973D0 (en) * | 1989-09-15 | 1989-11-01 | Auchincloss Thomas R | Effervescent tablets |
-
1995
- 1995-01-30 FR FR9501047A patent/FR2729858B1/en not_active Expired - Fee Related
-
1996
- 1996-01-30 WO PCT/FR1996/000157 patent/WO1996023510A1/en not_active Application Discontinuation
- 1996-01-30 JP JP8523313A patent/JPH10513170A/en active Pending
- 1996-01-30 AU AU46673/96A patent/AU4667396A/en not_active Abandoned
- 1996-01-30 US US08/875,632 patent/US5846564A/en not_active Expired - Fee Related
- 1996-01-30 EP EP96902310A patent/EP0804208A1/en not_active Withdrawn
- 1996-01-30 CA CA002211586A patent/CA2211586A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089606A (en) * | 1989-01-24 | 1992-02-18 | Minnesota Mining And Manufacturing Company | Water-insoluble polysaccharide hydrogel foam for medical applications |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440926B1 (en) * | 1997-04-14 | 2002-08-27 | The Procter & Gamble Company | Effervescent compositions and dry effervescent granules |
US20060177511A1 (en) * | 2002-01-16 | 2006-08-10 | 3M Innovative Properties Company | Antiseptic compositions and methods |
US8840932B2 (en) | 2002-01-16 | 2014-09-23 | 3M Innovative Properties Company | Antiseptic compositions and methods |
US9277750B2 (en) | 2002-01-16 | 2016-03-08 | 3M Innovative Properties Company | Antiseptic compositions and methods |
US20060246027A1 (en) * | 2005-05-02 | 2006-11-02 | Tanner Paul R | Personal care composition |
WO2011089584A1 (en) * | 2010-01-25 | 2011-07-28 | Modi-Mundipharma Pvt. Ltd | Process for the preparation of a granular oral composition |
IT202100003764A1 (en) * | 2021-02-18 | 2022-08-18 | Diego Zito | BIOCIDAL DETERGENT |
EP4046493A1 (en) * | 2021-02-18 | 2022-08-24 | Zito, Diego | Biocidal detergent |
Also Published As
Publication number | Publication date |
---|---|
JPH10513170A (en) | 1998-12-15 |
FR2729858A1 (en) | 1996-08-02 |
EP0804208A1 (en) | 1997-11-05 |
AU4667396A (en) | 1996-08-21 |
WO1996023510A1 (en) | 1996-08-08 |
FR2729858B1 (en) | 1997-04-18 |
CA2211586A1 (en) | 1996-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5008106A (en) | Method for reducing the microbial content of surfaces with a microbiocidal, anhydrous complex of PVP-H2 O2 | |
US5846564A (en) | Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection | |
US5122370A (en) | Method for treating acne vulgaris with a composition containing a stable, high purity, substantially anhydrous complex of PVP-H2 O.sub.2 | |
US4824664A (en) | Effervescent couples, histamine H2 -antagonist effervescent compositions containing them and their preparation | |
JP3517233B2 (en) | Reaction injection foaming system | |
CA1135190A (en) | Effervescent analgesic powder | |
KR940002659B1 (en) | Process for therapeutic compositions | |
US5260304A (en) | Pharmaceutical preparation binding with gastric acid | |
US5616347A (en) | Chlorine dioxide skin medicating compositions for preventing irritation | |
JP2012001557A (en) | Improved fast disintegrating tablet | |
BG64074B1 (en) | Pharmaceutical compositions containing effervescent acid base pair | |
WO1991007184A1 (en) | SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2? | |
KR100833469B1 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
US5861141A (en) | Pharmaceutical formulations of cefaclor | |
EP0500851B1 (en) | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure | |
EP0367056A2 (en) | A granulating composition and method | |
US3506756A (en) | Use of adipic acid as a tableting lubricant | |
JP2002539140A (en) | Iodine preparation | |
ZA200509026B (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
WO1996032012A1 (en) | Effervescent granular preparation for keeping cut flower freshness | |
TW200812645A (en) | Tetracycline package formulations | |
JPH02211A (en) | Pharmacological composition and production thereof | |
JP2001514194A (en) | Compressed chloramine T tablets and method for producing the same | |
JP4484477B2 (en) | Solid dialdehyde composition having antibacterial activity and method for producing the same | |
JPH01132504A (en) | Chloroisocyanurate composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SOCIETE CIVILE MISSION, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BESSE, JEROME;REEL/FRAME:009244/0889 Effective date: 19970811 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: GALENIX DEVELOPPEMENT, FRANCE Free format text: MERGER;ASSIGNOR:SOCIETE CIVILE MISSION;REEL/FRAME:013922/0545 Effective date: 19920612 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20101208 |